|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM109389263 |
| 003 |
DE-627 |
| 005 |
20231222151231.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0365.xml
|
| 035 |
|
|
|a (DE-627)NLM109389263
|
| 035 |
|
|
|a (NLM)11019371
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ohuchi, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.10.2000
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a To determine whether administration of estrogen or gestagen prior to luteinizing hormone-releasing hormone (LH-RH) agonist prevents disease flare in prostate cancer patients, we pretreated the patients with either diethylstilbestrol diphosphate (DES-P) 300 mg daily (N = 17) or chlormadinone acetate (CMA) 100 mg daily (N = 16) or none (N = 16) for two weeks before the initial injection of leuprolide acetate (L). Blood samples for prostatic specific antigen (PSA), testosterone (T), and luteinizing hormone were collected before CMA and DES-P administration, before and at 2, 7, 14, 28, 56, and 84 days after the first administration of leuprolide. The treatment with DES-P and CMA prior to LH-RH agonist induced an early decline of PSA. The mean PSA level showed no significant secondary rise in those patients with pretreatment after L administration. In the patients pretreated with DES-P or CMA, the mean serum T level never exceeded the pretreatment baseline after L administration. On the other hand, in the patients without DES-P or CMA, both serum T and PSA levels increased after the first administration of L. These results clearly demonstrate that pretreatment with DES-P 300 mg daily or CMA 100 mg daily for 2 weeks is quite effective to prevent disease flare after the first administration of L in patients with prostatic cancer
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Antineoplastic Agents, Hormonal
|2 NLM
|
| 650 |
|
7 |
|a Autacoids
|2 NLM
|
| 650 |
|
7 |
|a Progesterone Congeners
|2 NLM
|
| 650 |
|
7 |
|a Chlormadinone Acetate
|2 NLM
|
| 650 |
|
7 |
|a 0SY050L61N
|2 NLM
|
| 650 |
|
7 |
|a Testosterone
|2 NLM
|
| 650 |
|
7 |
|a 3XMK78S47O
|2 NLM
|
| 650 |
|
7 |
|a Diethylstilbestrol
|2 NLM
|
| 650 |
|
7 |
|a 731DCA35BT
|2 NLM
|
| 650 |
|
7 |
|a Luteinizing Hormone
|2 NLM
|
| 650 |
|
7 |
|a 9002-67-9
|2 NLM
|
| 650 |
|
7 |
|a fosfestrol
|2 NLM
|
| 650 |
|
7 |
|a A0E0NMA80F
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 650 |
|
7 |
|a Leuprolide
|2 NLM
|
| 650 |
|
7 |
|a EFY6W0M8TG
|2 NLM
|
| 700 |
1 |
|
|a Noguchi, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kinoshita, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hosaka, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kawasaki, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Miura, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kondo, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Harada, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 46(2000), 8 vom: 01. Aug., Seite 531-6
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:46
|g year:2000
|g number:8
|g day:01
|g month:08
|g pages:531-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 46
|j 2000
|e 8
|b 01
|c 08
|h 531-6
|